The Vox Markets Podcast cover art

The Vox Markets Podcast

The Vox Markets Podcast

By: Vox Markets Podcast
Listen for free

About this listen

 Vox Markets is revolutionising the way companies engage with all classes of shareholders. Listen here to interviews with company executives and sell-side analysts and fund managers discuss their investment insights.Vox Markets Economics Personal Finance
Episodes
  • 2301: Tharisa set for huge growth amidst backdrop of rising PGM prices

    2301: Tharisa set for huge growth amidst backdrop of rising PGM prices
    Jan 30 2026
    Tharisa has a well-established track record of chrome and platinum group metals production, and is now on the cusp of delivering significant growth through a move underground at its flagship South African mine and the establishment of new lines of production from a major new Zimbabwean project. The company is keeping a tight rein on costs, even as rising commodities prices push margins up, and it's in that context that the shares have doubled over the past 12 months. Even so, CEO Phoevos Pouroulis still argues that the company is undervalued compared to its peers. He joins us to tell us why he thinks that, and to provide details of what will happen next
    Show More Show Less
    20 mins
  • 2300: Quantum Data Energy: Q1 Update and Strategy Outlook

    2300: Quantum Data Energy: Q1 Update and Strategy Outlook
    Jan 30 2026
    In this interview, Quantum Data Energy #MAST CEO Pieter Krügel joins Vox Markets to discuss the Company’s Q1 investor update, recent re-branding, and the strategic evolution of the business. Pieter outlines how Quantum Data Energy is building on its flexible generation foundations, why data led infrastructure is becoming increasingly relevant, and how the Company is approaching growth with a clear focus on execution and capital discipline.
    Show More Show Less
    6 mins
  • 2299: Poolbeg Pharma: POLB 001 Clinical Data Published — What’s Next for This Immunomodulatory Asset?

    2299: Poolbeg Pharma: POLB 001 Clinical Data Published — What’s Next for This Immunomodulatory Asset?
    Jan 29 2026
    Following the publication of a peer-reviewed paper in Frontiers in Immunology detailing results from the POLB 001 LPS challenge trial, we catch up with Poolbeg Pharma’s CEO Jeremy Skillington and COO Liam Tremble.
    Show More Show Less
    9 mins
No reviews yet